As President, Development and Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines and overseeing medical activities across the company to bring meaningful new treatment options to patients.
Shreeram’s organization leads the development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while generating the evidence needed to ensure our medicines can reach all patients who can benefit. As part of the Novartis strategy, Shreeram and his team play a central role in driving the company’s mid- to long-term growth and delivering on its purpose to improve and extend people’s lives, with a strong pipeline that includes investigational high-value treatments for cardiovascular, renal and immunological conditions, neurological disorders and various forms of cancer.
It’s a true privilege and great responsibility to develop and deliver the next generation of transformational medicines founded in innovative science.
Shreeram is passionate about partnering with patients and physicians to change medical practice, recognizing the hope and trust of clinical trial participants and those who treat and care for them. He has dedicated his professional career to improving patients’ lives, first as an academic clinician and then as a drug developer and business leader.
